NCT06749600 Clinical Management and Outcomes of Primary Ovarian Leiomyosarcoma
| NCT ID | NCT06749600 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Azienda USL Reggio Emilia - IRCCS |
| Condition | Primary Ovarian Leiomyosarcoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-06-14 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2024-06-14 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This observational study aims to gather comprehensive data on primary ovarian leiomyosarcoma (POLMS). This extremely rare malignancy accounts for less than 3% of primary ovarian malignancies and has an incidence of only 1% among ovarian cancers. This national, retrospective and prospective multicenter study will collect and analyze historical cases of POLMS with remote diagnoses accessed through clinical case reviews and newly identified cases. The study aims to expand a previously identified series of 113 cases described in the literature, uncovering patterns in diagnosis, treatment, and outcomes and ultimately establishing evidence-based guidelines for the optimal management of this rare and aggressive cancer.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of primary leiomyosarcoma of the ovary; * Patients diagnosed with POLMS for whom data relating to diagnosis and treatment are available. * Aged between 18 and 99 years Exclusion Criteria: \- All patients with other forms of ovarian sarcoma (rhabdomyosarcomas, fibrosarcomas, stromal cell sarcomas) and patients diagnosed with leiomyosarcoma of the uterus will be excluded.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06749600 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 99 Years, studying Primary Ovarian Leiomyosarcoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06749600 currently recruiting?
Yes, NCT06749600 is actively recruiting participants. Contact the research team at vincenzodario.mandato@ausl.re.it for enrollment information.
Where is the NCT06749600 trial being conducted?
This trial is being conducted at Modena, Italy, Parma, Italy, Reggio Emilia, Italy, Avellino, Italy and 6 additional locations.
Who is sponsoring the NCT06749600 clinical trial?
NCT06749600 is sponsored by Azienda USL Reggio Emilia - IRCCS. The trial plans to enroll 30 participants.